Cited by 176Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

Open access

Liska, David, Chen, Chin-Tung, Bachleitner-Hofmann, Thomas, Christensen, James G., Weiser, Martin R.·2011·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-0568PMC PMC3033451

Open this paper in CoChat — free account

Abstract

Purpose: Cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), is active in colorectal cancer (CRC). However, response rates range from only 10% to 20%. Here, we investigate hepatocyte growth factor (HGF)-dependent mesenchymal-epithelial transition factor (MET) activation as a mediator of cetuximab resistance through signal diversification in CRC cell lines. Experimental Design: DiFi, GEO, and LIM1215 cells were treated with varying concentrations and combinations of EGF, HGF, cetuximab, and PHA-665752 (a highly specific MET kinase inhibitor). Biological end points included proliferation, cell cycle arrest, and apoptosis. Proliferation was measured using WST-1 assays and synergy investigated via isobolograms. Expression and signaling were examined using immunoblotting. Results: EGFR and MET are coexpressed in these CRC cell lines, and dual receptor activation synergistically increased proliferation. Cetuximab inhibited cell growth by 60%–80% with an associated dephosphorylation of EGFR, MAPK, and/or AKT. Addition of HGF to cetuximab-treated cells phosphorylated MET, but not EGFR or ErbB3, restimulated the MAPK and AKT pathways, restored cell proliferation, and rescued cells from G1 arrest and apoptosis. Importantly, this effect could be abrogated by inhibiting MET activation with PHA-665752 or by downregulating MET expression with RNAi. Conclusions: HGF-induced MET activation is a novel mechanism of cetuximab resistance in CRC. Inhibition of the HGF-MET pathway may improve response to EGFR inhibitors in CRC, and combination therapy should be further investigated. Clin Cancer Res; 17(3); 472–82. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-0568

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Statistics, 2007
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“Mutations in BRAF, the serine protein recruited by KRAS, which occur in approximately 3%-10% of KRAS wild-type CRC cancer patients are associated with resistance to monoclonal antibodies targeting EGFR (18-20).”
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485

Show all 54 references

Sorted by citations

The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,076
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P. J., Cameron, S. B., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C. A., Petruzzelli, L., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.17 · Cited by 968
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
Primrose, J. M., Falk, S. J., Finch-Jones, M., Valle, J. W., O'Reilly, D. A., Siriwardena, A. K., Hornbuckle, J., Peterson, M. C., Rees, M., Iveson, T. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70105-6 · Cited by 433
Cancer associated fibroblasts: An essential role in the tumor microenvironment
Tao, L., Huang, G., Song, H., Chen, Y., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6497 · Cited by 351
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
Determinants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 262
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Bradley, C. A., Salto‐Tellez, M., Laurent‐Puig, P., Bardelli, A., Rolfo, C. D., Tabernero, J. M., Khawaja, H. A., Lawler, M., Johnston, P. G., & Schaeybroeck, S. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.40 · Cited by 227
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2 -Amplified Gastric Cancer Cells
Chen, C., Kim, H., Liska, D., Gao, S. P., Christensen, J. G., & Weiser, M. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0754 · Cited by 179
Self-citation
Bispecific antibody drug conjugates: Making 1+1>2
Gu, Y., Wang, Z., & Wang, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.009 · Cited by 171
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Emburgh, B. O. V., Bianchi, A. S., Nicolantonio, F. D., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 162
Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Troiani, T., Martinelli, E., Napolitano, S., Vitagliano, D., Ciuffreda, L. P., Costantino, S., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0423 · Cited by 150
Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways
Meng, X., Zhao, Y., Han, B. R., Zha, C., Zhang, Y., Li, Z., Wu, P., Qi, T., Jiang, C., Liu, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14036-x · Cited by 149
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
Argiris, A. E., Kotsakis, A. P., HOANG, T. N., Worden, F. P., Savvides, P. S., Gibson, M. K., Gyanchandani, R., Blumenschein, G. R., Chen, H. X., Grandis, J. R., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds245 · Cited by 148
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2340-t · Cited by 146
Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Karagonlar, Z. F., Koç, D., İşcan, E., Erdal, E., & Atabey, N. (2016) · Cancer Science · doi:10.1111/cas.12891 · Cited by 132
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment
Owusu, B. Y., Galemmo, R. A., Janetka, J. W., & Klampfer, L. (2017) · Cancers · doi:10.3390/cancers9040035 · Cited by 140
MET: A Critical Player in Tumorigenesis and Therapeutic Target
Graveel, C. R., Tolbert, D., & Vande Woude, G. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009209 · Cited by 128
HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment
Hartmann, S., Bhola, N. E., & Grandis, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0951 · Cited by 129
Epidermal Growth Factor Signaling in Transformed Cells
Lindsey, S. C., & Langhans, S. A. (2014) · International review of cytology · doi:10.1016/bs.ircmb.2014.10.001 · Cited by 123
Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
Smyth, E. C., Sclafani, F., & Cunningham, D. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s44941 · Cited by 115
Signaling cross-talk in the resistance to HER family receptor targeted therapy
Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 118
TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
Hobor, S., Emburgh, B. O. V., Crowley, E. H., Misale, S., Nicolantonio, F. D., & Bardelli, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0774 · Cited by 117
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2752 · Cited by 110
Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
Boeckx, C., Baay, M. F. D., Wouters, A., Specenier, P. M., Vermorken, J. B., Peeters, M., & Lardon, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0013 · Cited by 110
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
Troiani, T., Napolitano, S., Vitagliano, D., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., Ciardiello, D., Ciardiello, F., & Martinelli, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2181 · Cited by 104
Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models
Rosa, R., Marciano, R., Malapelle, U., Formisano, L., Nappi, L., D’Amato, C., D'Amato, V., Damiano, V., Marfè, G., Vecchio, S. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1050 · Cited by 104
S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Burbridge, M. F., Bossard, C. J., Saunier, C., Fejes, I., Bruno, A., Léonce, S., Ferry, G., Violante, G. D., Bouzom, F., Cattan, V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0075 · Cited by 94
Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
Corso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 96
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
Sellmann, C., Doerner, A., Knuehl, C., Rasche, N., Sood, V. D., Krah, S., Rhiel, L., Messemer, A., Wesolowski, J. S., Schuette, M., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753491 · Cited by 93
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Madoz‐Gúrpide, J., Zazo, S., Chamizo, C., Casado, V., Caramés, C., Gavín, E., Cristóbal, I., García‐Foncillas, J., & Rojo, F. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0633-7 · Cited by 91
Mechanisms of acquired resistance to tyrosine kinase inhibitors
Chen, Y., & Fu, L. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.10.007 · Cited by 89
Kirsten Ras* oncogene: Significance of its discovery in human cancer research
Tsuchida, N., Murugan, A. K., & Grieco, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8773 · Cited by 94
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Receptor tyrosine kinases: biological functions and anticancer targeted therapy
Zhang, N., & Li, Y. (2023) · MedComm · doi:10.1002/mco2.446 · Cited by 97
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1677 · Cited by 84
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82
c-Met targeting in advanced gastric cancer: An open challenge
Marano, L., Chiari, R., Fabozzi, A., Vita, F. D., Boccardi, V., Roviello, G., Petrioli, R., Marrelli, D., Roviello, F., & Patriti, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.028 · Cited by 81
A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
Eng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30049 · Cited by 72
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Napolitano, S., Martini, G., Rinaldi, B., Martinelli, E., Donniacuo, M., Berrino, L., Vitagliano, D., Morgillo, F., Barra, G., De Palma, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0020 · Cited by 72
MicroRNAs in cancer drug resistance: Basic evidence and clinical applications
Ghasabi, M., Mansoori, B., Mohammadi, A., Duijf, P. H. G., Shomali, N., Shirafkan, N., Mokhtarzadeh, A., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26810 · Cited by 71
The somatic mutation landscape of premalignant colorectal adenoma
Lin, S., Raju, G. S., Huff, C. D., Ye, Y., Gu, J. H., Chen, J., Hildebrandt, M. A. T., Liang, H., Menter, D. G., Morris, J. S., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313573 · Cited by 69
Targeting Receptor Kinases in Colorectal Cancer
García‐Aranda, M., & Redondo, M. (2019) · Cancers · doi:10.3390/cancers11040433 · Cited by 75
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity
Castoldi, R., Ecker, V., Wiehle, L., Majety, M., Busl-Schuller, R., Asmussen, M., Nopora, A., Jucknischke, U., Osl, F., Kobold, S., et al. (2013) · Oncogene · doi:10.1038/onc.2013.245 · Cited by 67
Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial–Mesenchymal Transition, and Metastasis
Dzobo, K., & Sinkala, M. (2021) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2021.0025 · Cited by 62
cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
Sohn, J., Liu, S., Parinyanitikul, N., Lee, J., Hortobágyi, G. N., Mills, G. B., Ueno, N. T., & Gonzalez-Angulo, A. M. (2014) · Journal of Cancer · doi:10.7150/jca.9696 · Cited by 58
The c-Met receptor: Implication for targeted therapies in colorectal cancer
Qamsari, E. S., Ghaderi, S. S., Zarei, B., Dorostkar, R., Bagheri, S., Jadidi‐Niaragh, F., Somi, M. H., & Yousefi, M. (2017) · Tumor Biology · doi:10.1177/1010428317699118 · Cited by 60
MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms
Joosten, S. P. J., Zeilstra, J., van Andel, H., Mijnals, R. C. D., Zaunbrecher, J., Duivenvoorden, A. A. M., van de Wetering, M., Clevers, H. C., Spaargaren, M., & Pals, S. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.008 · Cited by 58
Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
Moosavi, F., Giovannetti, E., Peters, G. J., & Firuzi, O. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103234 · Cited by 58
Role of cMET in the Development and Progression of Colorectal Cancer
Pérez-Vargas, J. C. S., Biondani, P., Maggi, C., Gariboldi, M., Gloghini, A., Inno, A., Volpi, C. C., Gualeni, A. V., Bartolomeo, M. D., de Braud, F., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918056 · Cited by 59
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
Kearns, J. D., Bukhalid, R. A., Sevecka, M., Tan, G., Gerami-Moayed, N., Werner, S. L., Kohli, N., Burenkova, O. V., Sloss, C. M., King, A. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0772 · Cited by 58
Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c‐Met‐Mediated Epithelial‐to‐Mesenchymal Transition
Hsieh, Y., Liao, C., Chen, W., Pai, J., & Weng, M. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26128 · Cited by 55
Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation
Miyata, K., Takemoto, A., Okumura, S., Nishio, M., & Fujita, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-04324-1 · Cited by 55
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer
Voutsina, A., Tzardi, M. N., Kalikaki, A., Zafeiriou, Z., Papadimitraki, E., Papadakis, M., Mavroudis, D., & Georgoulias, V. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.150 · Cited by 55
Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)
Shimoyama, S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.218 · Cited by 53
Loss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon
Hamilton, K. E., Chatterji, P., Lundsmith, E. T., Andres, S. F., Giroux, V., Hicks, P. D., Noubissi, F. K., Spiegelman, V. S., & Rustgi, A. K. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0224 · Cited by 52
Gene of the month: HGF
Fajardo-Puerta, A. B., Prado, M. M., Frampton, A. E., & Jiao, L. R. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203575 · Cited by 51
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa, L., Bozzarelli, S., Pietrantonio, F., Cordio, S., Lonardi, S., Toppo, L., Zaniboni, A., Bordonaro, R., Di Bartolomeo, M., Tomasello, G., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.004 · Cited by 50
Modulation of c‐Met signaling and cellular sensitivity to radiation
Bhardwaj, V., Cascone, T., Cortez, M. A., Amini, A., Evans, J. D., Komaki, R. U., Heymach, J. V., & Welsh, J. W. (2013) · Cancer · doi:10.1002/cncr.27965 · Cited by 50
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
Goldberg, R. M., Montagut, C. O., Wainberg, Z. A., Ronga, P., Audhuy, F., Taı̈eb, J., Stintzing, S., Siena, S., & Santini, D. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000353 · Cited by 51
Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav, K. P. S., Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.09.04 · Cited by 51
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer
Graham, D. M., Coyle, V. M., Kennedy, R. D., & Wilson, R. H. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0312-y · Cited by 49
Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance
Joosten, S. P. J., Spaargaren, M., Clevers, H. C., & Pals, S. T. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188437 · Cited by 47
Current advances of targeting HGF/c-Met pathway in gastric cancer
Anestis, A., Zoi, I., & Karamouzis, M. V. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.42 · Cited by 44
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)
Stahl, M., Maderer, A., Lordick, F., Mihaljević, A. L., Kanzler, S., Hoehler, T., Thuss-Patience, P. C., Mönig, S., Kunzmann, V., Schroll, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.01.079 · Cited by 43
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 43
Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines
Heindl, S., Eggenstein, E., Keller, S., Kneißl, J., Keller, G., Mutze, K., Rauser, S., Gasteiger, G., Drexler, I., Hapfelmeier, A., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1128-4 · Cited by 41
Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer
Yamada, T., Takeuchi, S., Kita, K., Bando, H., Nakamura, T., Matsumoto, K., & Yano, S. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182398e69 · Cited by 44
MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure
Boccaccio, C., & Comoglio, P. M. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.008 · Cited by 42
Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor
Dai, W., Li, Y., Zhou, Q., Xu, Z., Sun, C., Tan, X., & Li, L. (2013) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12116 · Cited by 40
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
Formisano, L., D'Amato, V., Servetto, A., Brillante, S., Raimondo, L., Mauro, C. D., Marciano, R., Orsini, R. C., Cosconati, S., Randazzo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4636 · Cited by 42
Human colorectal cancer-derived carcinoma associated fibroblasts promote CD44-mediated adhesion of colorectal cancer cells to endothelial cells by secretion of HGF
Zhang, R., Qi, F., Shao, S., Li, G., & Feng, Y. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0914-y · Cited by 39
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines
Kneißl, J., Keller, S., Lorber, T., Heindl, S., Keller, G., Drexler, I., Hapfelmeier, A., Höfler, H., & Luber, B. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1479 · Cited by 38
Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
Song, N., Liu, S., Zhang, J., Liu, J., Xu, L., Liu, Y., & Qu, X. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045838 · Cited by 38
c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases.
Gayyed, M. F., El-Maqsoud, N. M. R. A., El-Heeny, A. A. E.-H., & Mohammed, M. F. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.072 · Cited by 38
KRAS mutant colorectal tumors
Brand, T. M., & Wheeler, D. L. (2012) · Small GTPases · doi:10.4161/sgtp.18751 · Cited by 37
MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance
Paulson, A. K., Linklater, E. S., Berghuis, B. D., App, C. A., Oostendorp, L. D., Paulson, J. E., Pettinga, J., Melnik, M. K., Woude, G. F. V., & Graveel, C. R. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0042 · Cited by 38
Moderate hyperthermic heating encountered during thermal ablation increases tumor cell activity
Markezana, A., Ahmed, M., Kumar, G., Zorde‐Khvalevsky, E., Rozenblum, N., Galun, E., & Goldberg, S. N. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1714084 · Cited by 36
The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p
Zhang, X., Wen, L., Chen, S., Zhang, J., Ma, Y., Hu, J., Yue, T., Wang, J., Zhu, J., Bu, D., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1155-9 · Cited by 35
Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer
Takahashi, N., Furuta, K., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., Iwasa, S., Okita, N. T., Takashima, A., Kato, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6753 · Cited by 35
Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
Hwang, K., Yoon, J. H., Lee, J., & Lee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9010039 · Cited by 37
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer
Mehra, R., Serebriiskii, I. G., Dunbrack, R. L., Robinson, M. K., Burtness, B. A., & Golemis, E. A. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.002 · Cited by 34
MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells
Boccaccio, C., Luraghi, P., & Comoglio, P. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1088 · Cited by 34
Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer
Lee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 33
Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy
Wei, S., Hu, W., Feng, J., & Geng, Y. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00960-x · Cited by 31
Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells
Chen, H., Jiang, Y., Lin, C.-M., Tsai, S., Peng, S., Fushiya, S., Hour, M., & Yang, J. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1941 · Cited by 30
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 30
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies
Flynn, M. J., & Larkin, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1369956 · Cited by 30
Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms
Shyamsunder, S., Lu, Z., Takiar, V., & Waltz, S. E. (2025) · Oncotarget · doi:10.18632/oncotarget.28747 · Cited by 28
Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
Yang, J., Li, S., Wang, B., Wu, Y., Chen, Z., Lv, M., Lin, Y., & Yang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-5140-9 · Cited by 29
Novel strategy for a bispecific antibody: induction of dual target internalization and degradation
Lee, J. M., Lee, S. H., Hwang, J.-W., Oh, S. J., Kim, B., Jung, S. W., Shim, S.-H., Lin, P. W., Lee, S. B., Cho, M.-Y., et al. (2016) · Oncogene · doi:10.1038/onc.2015.514 · Cited by 26
Analysis of the Effect of Increased α2,3-Sialylation on RTK Activation in MKN45 Gastric Cancer Spheroids Treated with Crizotinib
Balmaña, M., Diniz, F., Feijão, T., Barrias, C. C., Mereiter, S., & Reis, C. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030722 · Cited by 27
Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
Kishiki, T., Ohnishi, H., Masaki, T., Ohtsuka, K., Ohkura, Y., Furuse, J., Watanabe, T., & Sugiyama, M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2401-4 · Cited by 25
Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Hatch, A. J., Sibley, A. B., Starr, M. D., Brady, J. C., Jiang, C., Jia, J., Bowers, D. L., Pang, H., Owzar, K., Niedzwiecki, D., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.806 · Cited by 23
Characterization and functional analysis of a slow-cycling subpopulation in colorectal cancer enriched by cell cycle inducer combined chemotherapy
Wu, F., Mu, L., Li, X.-L., Hu, Y., Liu, H., Han, L., & Gong, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19638 · Cited by 25

Authors: Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Authors' Affiliations: 1Departments of Surgery, Memorial Sloan-Kettering Cancer Center, New York; 2Department of Cancer Research, Pfizer Global Research and Development, La Jolla Laboratories, La Jolla, California
Corresponding author: Weiser, Martin R.
ORCID: Liska, David
Chen, Chin-Tung
Christensen, James G.
Weiser, Martin R.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2011-02-01
Volume: 17
Issue: 3
Pages: 472-482
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-0568
PMC: PMC3033451
OpenAlex: W2133129337
Cited by: 176
References: 54
Citations by year: 2026: 7 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 9 · 2019: 7 · 2018: 6 · 2017: 23 · 2016: 17 · 2015: 22 · 2014: 23 · 2013: 18 · 2012: 11
FWCI: 5.37
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (T32CA009501)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: hepatocyte growth factor, MET activation, cetuximab resistance, EGFR inhibition, colorectal cancer, mesenchymal-epithelial transition, PHA-665752, MAPK signaling, Akt signaling, cell proliferation, apoptosis, G1 cell cycle arrest, combination therapy
MeSH terms: Cetuximab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Colorectal Neoplasms, Signal Transduction, Transcriptional Activation, Hepatocyte Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Cell Line, Tumor, Cell Proliferation, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks